We have located links that may give you full text access.
Timing of venous thromboprophylaxis in isolated severe pelvic fracture: Effect on mortality and outcomes.
Injury 2019 March
INTRODUCTION: Optimal timing of pharmacological thromboprophylaxis (VTEp) in patients with severe pelvic fractures remains unclear. The high risk of venous thromboembolic (VTE) complications after severe pelvic fractures supports early VTEp however concern for fracture-associated hemorrhage can delay initiation. Patients with pelvic fractures also frequently have additional injuries that complicate the interpretation of the VTEp safety profiles. To minimize this problem, the study included only patients with isolated severe pelvic fractures.
MATERIALS AND METHODS: The Trauma Quality Improvement Program was used to collect patients with blunt severe pelvic fractures (AIS > 3) who received VTEp with unfractionated heparin (UH) or low-molecular-weight heparin (LMWH). Patients with head, chest, spine, and abdominal injuries AIS > 3, or those with angio or operative intervention prior to VTEp were excluded. The study population was stratified according to timing of VTEp, early (<48 h) and late (>48 h). Outcomes included in-hospital mortality and VTE.
RESULTS: 2752 patients were included in the study. Overall, 2007 patients (72.9%) received early VTEp, while 745 (27.1%) received late VTEp. LMWH was administered in 2349 (85.4%) and UH in 403 (14.6%). Late VTEp was associated with significantly higher incidence of VTE (4.3% vs. 2.2%, p = 0.004). Logistic regression identified late VTEp as an independent risk factor for VTE (OR 1.93, p = 0.009) and mortality (OR 4.03, p = 0.006). LMWH was an independent factor protective for both VTE and mortality (OR 0.373, p < 0.001, OR 0.266, p = 0.009, respectively).
CONCLUSION: In isolated severe pelvic fractures, early VTEp is independently associated with improved survival and fewer VTE. LMWH may be preferred over UH for this purpose.
MATERIALS AND METHODS: The Trauma Quality Improvement Program was used to collect patients with blunt severe pelvic fractures (AIS > 3) who received VTEp with unfractionated heparin (UH) or low-molecular-weight heparin (LMWH). Patients with head, chest, spine, and abdominal injuries AIS > 3, or those with angio or operative intervention prior to VTEp were excluded. The study population was stratified according to timing of VTEp, early (<48 h) and late (>48 h). Outcomes included in-hospital mortality and VTE.
RESULTS: 2752 patients were included in the study. Overall, 2007 patients (72.9%) received early VTEp, while 745 (27.1%) received late VTEp. LMWH was administered in 2349 (85.4%) and UH in 403 (14.6%). Late VTEp was associated with significantly higher incidence of VTE (4.3% vs. 2.2%, p = 0.004). Logistic regression identified late VTEp as an independent risk factor for VTE (OR 1.93, p = 0.009) and mortality (OR 4.03, p = 0.006). LMWH was an independent factor protective for both VTE and mortality (OR 0.373, p < 0.001, OR 0.266, p = 0.009, respectively).
CONCLUSION: In isolated severe pelvic fractures, early VTEp is independently associated with improved survival and fewer VTE. LMWH may be preferred over UH for this purpose.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app